Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Sutro Biopharma (NASDAQ: STRO) and maintains a price target of $60 for the stock. This endorsement suggests confidence in the company's performance and potential growth in the market.